Generic Name: ombitasvir/paritaprevir/ritonavir
Abbreviation: OBV/PTV/r or PrO
Other Market Name: Viekirax (Europe)
Drug Class: Multi-Class Combination Drugs
Approval Status: Approved
Generic Version Available: No
Experimental Code: ABT-267 + ABT-450/r
FDA-approved with ribavirin for the treatment of chronic HCV genotype 4 infection in people without decompensated cirrhosis.
- Ombitasvir is an HCV NS5A inhibitor. Paritaprevir is an HCV NS3/4A protease inhibitor. Ritonavir is a CYP3A4 inhibitor, which boosts paritaprevir, and does not have specific activity against HCV.
- Technivie was approved by the U.S. Food and Drug Administration for use by people living with hepatitis C on July 24, 2015.
- In clinical trials, 100 percent of participants were cured with 12 weeks of therapy.
Lab testing in the first four weeks of treatment is recommended as Technivie may cause liver enzymes to elevate.
Adult Dose: The recommend dose of Technivie is two tablets taken orally once daily (in the morning) with a meal. Follow additional dosing instructions for ribavirin.
Pediatric Dose: N/A
Dosing Info: Treatment is for 12 weeks. Technivie may be prescribed without ribavirin for treatment-naive patients who cannot take ribavirin. For specific treatment recommendations, see Hepatitis C Treatment-Naive Recommendations or Hepatitis C Re-treatment Recommendations.
The side effects associated with Technivie are considered mild. When prescribed with ribavirin, the most common are weakness, fatigue, nausea, insomnia, and itching and other skin reactions.
- Before taking this medication, tell your medical provider and pharmacist about any drugs, supplements and herbs you take, whether prescribed, over-the-counter or illicit.
- Do not use this product if you use ethinyl estradiol-containing medicines (such as some birth control products).
- Technivie may interact with drugs and herbs that are metabolized in the liver and intestines, such as phenytoin, rifampin, St. John’s wort and certain contraceptives. Additional drug-drug interactions may occur and these are listed in Technivie’s full prescribing information. Potential interactions are listed at hep-druginteractions.org.
- Warning: Patients who are coinfected with hepatitis B and C who take this medication may be at risk of hepatitis B virus (HBV) reactivation. Before taking this medication, be sure your doctor has tested you for evidence of current or prior hepatitis B virus infection. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in serious hepatitis flares, liver failure, and death.
- When Technivie is prescribed with ribavirin, a drug that may harm fetuses, it should not be taken by pregnant women or those who are trying to become pregnant. Women of childbearing age and their male sexual partners must use two forms of birth control throughout treatment and for six months after treatment if ribavirin is prescribed.
- When not taken with ribavirin, the effects of Technivie on the developing fetus during pregnancy or on babies during breast-feeding are not well-studied.
For More Info: http://www.viekira.com
Co-Pay Program Info: http://www.hepmag.com/basics/hepatitis-c-basics/paying-hepatitis-c-treatment
Patient Assistance Program Info: http://www.hepmag.com/basics/hepatitis-c-basics/paying-hepatitis-c-treatment
Last Reviewed: January 4, 2019